Compare MLEC & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MLEC | GDTC |
|---|---|---|
| Founded | 2008 | 2018 |
| Country | Cayman Islands | Singapore |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6M | 16.9M |
| IPO Year | N/A | 2023 |
| Metric | MLEC | GDTC |
|---|---|---|
| Price | $0.24 | $1.32 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 382.7K | 41.7K |
| Earning Date | 01-30-2026 | 04-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $573,193.00 |
| Revenue This Year | $20.42 | $5.37 |
| Revenue Next Year | $30.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 170.36 | 63.03 |
| 52 Week Low | $0.21 | $1.29 |
| 52 Week High | $8.00 | $4.05 |
| Indicator | MLEC | GDTC |
|---|---|---|
| Relative Strength Index (RSI) | 30.35 | 31.87 |
| Support Level | $0.21 | $1.29 |
| Resistance Level | $0.32 | $1.60 |
| Average True Range (ATR) | 0.05 | 0.10 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 11.19 | 12.82 |
Moolec Science SA is a science-based ingredient company focused on producing real animal proteins in plants through Molecular Farming, a technology in the alternative protein landscape. Its purpose is to upgrade the taste, nutrition, and affordability of alternative protein products while building a more sustainable and equitable food system. The company has various products in its pipeline such as; TSP Valorasoy which is a soy protein product to produce vegetable proteins with texture and fibrousness similar to those of meat, Glaso, a safflower oil with high levels of gamma-linolenic acid, SPC2 which is a plant-based chymosin, YEEA1, an extract derived from a novel yeast biomass with specific properties, and others. The company's revenues arise from operations in Argentina.
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.